Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease

Inclusion Criteria: * Subjects who understand and sign the consent form for this study. * Age :20-80, males and females * Patients at least 6 months after Buerger's disease * Patients with a luminal stenosis of more than 50% on angiography * Rutherford class II-4, III-5 or III-6 * Subjects not eligible to undergo a revascularization or vascular bypass graft * Patients who can't treat with traditional medication and need a arthroplasty. * Patients whose lesion is 2\~6 cm2 in size * Duration of pain over Grade 4(11-point numeric scale) : \> 4 months Exclusion Criteria: * Subjects who cannot survive more than 6 months with critical other complications. * Patient with well-known active malignant tumor. * Patients who exceed normal reference values from following test : PAP smear screening, chest X-ray, PSA, mammogram, occult blood test * Patients in need of a immediate amputation and have a potentially life-threatening complications of critical ischemia * Patients with uncontrolled iliac artery obstruction of targeted areas. * Condition with targeted lower limb that have widespread necrosis or in need of amputation. * End-stage renal failure patients who depend on hemodialysis * Patients with uncontrolled diabetes mellitus (HbA1c \> 10%). * Treatment with immunosuppressant (prednisone \> 5mg/day). * Treatment with a anti-inflammatory drugs within 1 weeks prior to enrollment. * Women who are pregnant or breast feeding or planning to become pregnant during the study. * Subjects who have cerebrovascular accident within 6 months prior to inclusion in the study. * Patients with acute myocardial infarction, angina pectoris. * Subjects who had been underwent a cardiovascular surgery such as carotid endarterectomy, arterial aneurysm, bypass surgery and coronary bypass surgery within 3 months prior to inclusion in the study. * Participation in another clinical trial or treatment with a different investigational product within 3 months prior to inclusion in the study. * Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria